Bioselected oncolytic RNA virus delivered intratumorally; selectively infects and replicates in tumor cells to induce oncolysis and immunogenic cell death, releasing tumor antigens and danger signals that trigger type I interferon-driven innate sensing, dendritic cell activation/cross-presentation, and cytotoxic T-cell priming.
Intratumoral, receptor-targeted oncolytic RNA virus that selectively infects and replicates in tumor cells, causing direct oncolysis. Resultant release of tumor antigens and danger signals triggers type I interferon–driven innate sensing, activates dendritic cells with cross-presentation, and primes cytotoxic T cells, promoting systemic antitumor immunity and further intratumoral viral spread.
Receptor-targeted oncolytic virus binds the overexpressed entry receptor, infects receptor-positive tumor cells, replicates, and causes lytic oncolysis.
Human IgG1 monoclonal antibody immune checkpoint inhibitor that binds PD-L1, blocking its interaction with PD-1/B7.1 to restore T-cell antitumor activity; its Fc region can mediate NK cell–driven ADCC.
Human IgG1 monoclonal antibody that binds PD-L1, blocking its interaction with PD-1 and B7.1 to release PD-1 checkpoint inhibition and restore T-cell antitumor activity; its Fc region can trigger NK cell–mediated ADCC against PD-L1–expressing cells.
Avelumab binds PD-L1 on the cell surface; its IgG1 Fc engages Fcγ receptors on NK cells to trigger antibody‑dependent cellular cytotoxicity (ADCC), killing PD‑L1–expressing cells.
Fc-engineered anti-CD19 IgG1 monoclonal antibody that induces ADCC/ADCP and apoptosis of B cells.
Fc-engineered humanized anti-CD19 IgG1 monoclonal antibody that binds CD19 on B cells and, through enhanced Fc-gamma receptor engagement, increases ADCC and ADCP to deplete CD19-positive B cells and induce apoptosis.
Binds CD19 on B cells and engages Fcγ receptors on effector cells to mediate ADCC and ADCP; binding can also directly induce apoptosis of CD19+ cells.
Anti-CD20 IgG1 monoclonal antibody mediating complement activation and ADCC.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and induces cell killing primarily via complement-dependent cytotoxicity (CDC) and Fc-mediated antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), resulting in depletion of CD20-positive B cells; may also trigger direct apoptosis upon crosslinking.
Binds CD20 on B cells and triggers complement-dependent lysis and Fc-mediated ADCC/ADCP by effector cells; crosslinking can also induce apoptosis.
Anti-CD79b antibody–drug conjugate delivering MMAE, a microtubule-disrupting agent.
CD79b-directed antibody–drug conjugate; the anti-CD79b mAb binds B-cell malignancies, is internalized, and releases MMAE via a protease-cleavable linker. MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptotic death of the tumor cell.
The anti-CD79b ADC binds CD79B on B cells, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of the target cell.